Cure8 news brief
A combo that adds an α4β7 blocker to an IL-23 inhibitor showed higher endoscopic remission at Week 12 than either drug alone in a phase 2 Crohn’s trial, which could point to a new treatment strategy for people who’ve failed prior biologics.
Patients with moderate-to-severe Crohn’s (especially those with prior biologic treatment), clinicians treating IBD, researchers in IBD drug development, and people following AbbVie’s pipeline.
AbbVie reported phase 2 results for ABBV-466, a combination of risankizumab (Skyrizi) plus the α4β7 inhibitor trosunilimab, in moderate-to-severe Crohn’s disease. In a 300-patient randomized trial the combination met the primary endpoint of Week 12 endoscopic remission at a higher rate than either monotherapy.
The company also reported tissue-level signals (epithelial repair, barrier restoration, remodeling) at Weeks 12–24 and similar rates of serious adverse events across arms. A larger ~2,000-patient phase 2 program with substudies including Crohn’s and ulcerative colitis is underway.
This article summarizes Fierce Biotech’s reporting on AbbVie’s press/release and trial data; it does not provide full patient-level data, peer-reviewed publication, or detailed safety breakdowns. Cross-trial comparisons cited in the piece are preliminary and complicated by differences in prior-treatment history and patient populations.
Results come from a company-reported phase 2 trial reported by Fierce Biotech; full peer-reviewed results, detailed safety data, and longer-term outcomes were not provided in this article. Differences in trial populations limit cross-trial efficacy comparisons.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Longer-term and real-world data help patients and clinicians understand how well risankizumab and upadacitinib maintain clinical and endoscopic improvement over years of treatment, and early data on an investigational...
Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
